Harvey Capital Management Inc. Has $952,000 Stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST)

Harvey Capital Management Inc. grew its holdings in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) by 1,419.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 267,390 shares of the company’s stock after acquiring an additional 249,790 shares during the period. Harvey Capital Management Inc. owned 0.29% of Aquestive Therapeutics worth $952,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in the business. Verition Fund Management LLC bought a new stake in Aquestive Therapeutics in the third quarter worth approximately $995,000. State Street Corp grew its position in shares of Aquestive Therapeutics by 52.1% during the 3rd quarter. State Street Corp now owns 1,496,739 shares of the company’s stock worth $7,454,000 after buying an additional 512,682 shares during the period. Wellington Management Group LLP bought a new stake in shares of Aquestive Therapeutics in the 3rd quarter valued at $922,000. Chartwell Investment Partners LLC acquired a new position in shares of Aquestive Therapeutics during the 3rd quarter valued at $535,000. Finally, BNP Paribas Financial Markets boosted its stake in Aquestive Therapeutics by 252.2% during the third quarter. BNP Paribas Financial Markets now owns 18,826 shares of the company’s stock worth $94,000 after acquiring an additional 13,481 shares in the last quarter. 32.45% of the stock is owned by institutional investors.

Aquestive Therapeutics Price Performance

AQST opened at $2.97 on Wednesday. The firm’s fifty day moving average price is $3.41 and its two-hundred day moving average price is $4.21. The company has a market capitalization of $270.80 million, a price-to-earnings ratio of -6.60 and a beta of 2.67. Aquestive Therapeutics, Inc. has a 1 year low of $2.24 and a 1 year high of $6.23.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the stock. Cantor Fitzgerald began coverage on shares of Aquestive Therapeutics in a research note on Tuesday, December 17th. They issued an “overweight” rating and a $17.00 price target for the company. Leerink Partners boosted their target price on Aquestive Therapeutics from $12.00 to $13.00 and gave the company an “outperform” rating in a research report on Friday, October 25th. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Aquestive Therapeutics in a report on Friday, December 20th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $11.00.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.